New drug cocktail aims to beat back relapsed myeloma

NCT ID NCT03556332

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people with multiple myeloma that has come back after prior treatment. The study includes 41 participants and aims to see how many achieve complete remission. The goal is to find a more effective way to control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib, lenalidomide, dexamethasone, and daratumumab
What this could lead to: If successful, this combination could offer a more effective treatment option for people with multiple myeloma that has returned after previous therapies.
What could go wrong: This is a small, early-phase trial (41 participants) with no control group, so results may not apply broadly. The intensive drug regimen also carries risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Medical College of Wisconsin (Data Collection Only)

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
New York University

New York, New York, 10010, United States
Northwell Health

Manhasset, New York, 11030, United States
University of Alabama Comprehensive Cancer Center

Birmingham, Alabama, 35294, United States
Wake Forest University (Data Collection Only)

Winston-Salem, North Carolina, 27109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.